Cytochrome P450 (P450) and uridine 5′-diphosphoglucuronosyltransferase (UGT) are major metabolizing enzymes in the biotransformation of most drugs. Altered P450 and UGT activities are a potential cause of adverse drug-drug interaction (DDI). A method for the simultaneous evaluation of the activities of five P450s (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A) and four UGTs (UGT1A1, UGT1A4, UGT1A9, and UGT2B7) was developed using in vitro cocktail incubation and tandem mass spectrometry. The nine probe substrates used in this assay were phenacetin (CYP1A2), diclofenac (CYP2C9), S- (UGT1A1), trifluoperazine (UGT1A4), mycophenolic acid (UGT1A9), and naloxone (UGT2B7). This new method involves incubation of two cocktail doses and single cassette analysis. The two cocktail doses and the concentration of each probe substrate in vitro were determined to minimize mutual drug interactions among substrates. Cocktail A comprised phenacetin, diclofenac, S-mephenytoin, dextromethorphan, and midazolam, while cocktail B comprised SN-38, trifluoperazine, mycophenolic acid, and naloxone. In the incubation study of these cocktails, the reaction mixtures were pooled and simultaneously analyzed using liquid chromatography-tandem mass spectrometry. The method was validated by comparing inhibition data obtained from the incubation of each probe substrate alone with data from the cocktail method. The IC 50 value obtained in both cocktail and individual incubations were in agreement with values previously reported in the literature. This cocktail method offers a rapid and robust way to simultaneously evaluate phase I and II enzyme inhibition profiles of many new chemical entities. This new method will also be useful in the drug discovery process and for advancing the mechanistic understanding of drug interactions.
Introduction
Drug-drug interaction (DDI) can cause intense clinical complications, either by increasing the toxicity or by weakening the therapeutic efficacy of drugs. DDIs are one of the major reasons for drug withdrawal from the market (Huang et al., 2008) . Therefore, the early detection of DDIs is a critical factor of drug discovery that has led to the development of new screening methods for determining drug interactions. The present guidelines on pharmacokinetics and DDIs from the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) noted that phase I and phase II metabolizing enzymes are of clinical relevance.
Cytochrome P450 (P450) and uridine 5′-diphosphoglucuronosyltransferase (UGT) enzymes are the representative phase I and II enzymes, respectively, which play important roles in the metabolism of most drugs. In practice, P450s are the enzymes involved in the biotransformation of about 75% of all drugs metabolized by phase I enzymes (Guengerich, 2008) . UGT enzymes are involved in the biotransformation of about 20 to 30% of all drugs (Meech et al., 2012; Stingl et al., 2014) . Several in vitro screening methods for the simultaneous evaluation of potential P450-mediated DDIs have been developed, which include a mixture of P450 probe substrates in a cocktail incubation. The resultant P450-mediated metabolites are determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) Na et al., 2011; Spaggiari et al., 2014) . Recently, three screening methods for UGT enzyme activities using cocktail incubation and tandem mass spectrometry also have been reported (Gagez et al., 2012; Joo et al., 2014; Seo et al., 2014) .
A screening method for the simultaneous evaluation of P450 and UGT enzyme activities would accelerate the evaluation of the DDI potential of new chemical entities during drug development. To date, however, no such method has been developed. In this study, we report a new screening method that allows the simultaneous evaluation of the activities of five human hepatic P450 and four UGT enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, UGT1A4, UGT1A9, and UGT2B7). Their established probe substrates are used for the screening of potential inhibitory interactions of test compounds. We explored the optimal incubation conditions to avoid potential interactions between the cocktail compounds. Furthermore, we developed an analytical method for the simultaneous determination of five P450-specific substrate metabolites and four UGT-specific glucuronide metabolites using LC-MS/MS. (Easterbrook et al., 2001; Uchaipichat et al., 2004) . The incubation mixtures (final volume, 100 μL) for the cocktail A set contained 0.25 mg/mL microsomal protein, 0.1 M potassium phosphate buffer (pH 7.4), and various P450 enzyme-
specific substrates or a substrate cocktail A set. After a 5-min pre-incubation at 37ºC, the reactions were initiated by adding a NADPH-generating system containing 3.3 mM G6P, 1.3 mM β-NADP + , 3.3 mM MgCl 2 , and 500 unit/mL G6PDH, and further incubated for 15 min at 37ºC in a thermoshaker . The incubation mixtures (final volume, 100 μL)
for the cocktail B set consisted of 0.25 mg/mL microsomal protein, 25 μ g/mL alamethicin, 0.1 M Tris-HCl (pH 7.4), 10 mM MgCl 2 , and various UGT enzyme-specific substrates or a substrate cocktail B set (Joo et al., 2014) . After pre-incubation on ice for 15 min, the reactions were initiated by the addition of 5 mM UDPGA, and incubated for 1 h at 37°C. (Joo et al., 2014 
Comparison of the Cocktail and Individual Substrates for Inhibition Screening.
Known inhibitors of specific P450 and UGT enzymes (α-naphthoflavone for CYP1A2;
sulfaphenazole for CYP2C9; S-benzylnirvanol for CYP2C19; quinidine for CYP2D6; ketoconazole for CYP3A4; atazanavir for UGT1A1; hecogenin for UGT1A4; niflumic acid UGT1A9; and mefenamic acid for UGT2B7) were incubated with each substrate cocktail set and with the individual substrates alone and the results were compared. The incubations were performed (as described above) with various inhibitor concentrations and all incubations were performed in triplicate. Furafylline, paroxetine and troleandomycin were pre-incubated for 10 min at 37 °C with HLMs and an NADPH-generating system (as described above). The reactions were initiated by the addition of the individual or cocktail substrate. With the exception of the addition of P450-or UGT-isoform-specific inhibitors, all other incubation conditions were as described above. 
Results
Substrate Selection and Optimization of Microsomal Incubations. The structures of the P450 and UGT probe substrates, their metabolites, and the internal standard used in the assays are shown in Fig. 1 . In this study, we selected a P450-isoform specific probe substrate based on the preferred and accepted P450 substrates for assessing activity in vitro (Tucker et al., 2001; Na et al., 2011) . The UGT-isoform specific substrates were selected on the basis of their specificity and previously published data (Hanioka et al., 2001; Di Marco et al., 2005; Picard et al., 2005; Uchaipichat et al., 2006; Joo et al., 2014) . The probe substrates for the P450 and UGT isoforms were as follows: phenacetin, CYP1A2; diclofenac, CYP2C9; Smephenytoin, CYP2C19; dextromethorphan, CYP2D6; midazolam, CYP3A; SN-38, UGT1A1; trifluoperazine, UGT1A4; mycophenolic acid, UGT1A9; and naloxone, UGT2B7. transitions and optimal MS/MS collision energy are described in Table 1 reported studies (Joo and Liu, 2013; Pillai et al., 2013; Song et al., 2013) . The peak with a retention time of 3.3 min was identified as acetaminophen by comparing it with the retention time of an authentic standard.
Cocktail Dose Selection. The inhibition potential of each P450 or UGT substrate was evaluated by comparing the reaction of each metabolite in the single substrate incubations, to the response of the same metabolite formed in incubations with the two-substrate cocktail set.
The change in each P450 and UGT enzyme activity level was less than 15% in each cocktail set, compared with the individual incubation (Fig. 3) . The relative standard deviations (RSDs) ranged from 2.4-10.3% (n = 3) for the results of the cocktail incubation procedure.
Method Validation. The inter-and intra-day precision and accuracy of the method were determined by analyzing four QC replicates. The method accuracy was expressed as the percentage of the metabolite concentration measured in each sample relative to the known amount of metabolites added (Joo et al., 2014) . Calibration curves produced good correlation
coefficients for nine metabolites in the mixture (r > 0.999). The inter-day and intra-day accuracy and precision data for the five P450 and four UGT probe metabolites in human liver microsomal incubates are summarized in Table 2 and 3. Overall, the inter-and intra-day accuracy was 88.2-110.9% with a precision of less than 15.3%.
Validation of the Screening Method using Selective Inhibitors. The newly developed screening method used as a tool for determining P450 and UGT inhibition, was validated using known selective inhibitors of the isoforms (α-naphthoflavone, CYP1A2;
sulfaphenazole, CYP2C9; S-benzylnirvanol, CYP2C19; quinidine, CYP2D6; ketoconazole, CYP3A; atazanavir, UGT1A1; hecogenin, UGT1A4; niflumic acid, UGT1A9; and mefenamic acid, UGT2B7) with their corresponding substrates. The IC 50 value of each P450-and UGT-isoform selective inhibitor was estimated in both the individual and cocktail incubations ( Table 2 ). The inhibition curves (Fig. 4) show there was no substantial difference between the individual inhibitor profiles for the two different incubation methods (single vs.
cocktail).
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Discussion
Pharmacodynamic interactions between drugs alter the response to one or both drugs while also affecting their plasma concentrations (Singh, 2006) . Therefore, the risk of metabolismbased DDIs is always a potential problem to consider during the drug development process.
For this reason, in vitro drug interaction studies using HLMs are used for the early estimation and prediction of the in vivo drug interaction potential of new candidate drugs (Baranczewski et al., 2006) . Several LC-MS/MS-based P450 (Dierks et al., 2001; Kim et al., 2005; Smith et al., 2007; Zambon et al., 2010; Na et al., 2011; Pillai et al., 2013) or UGT (Gagez et al., 2012; Joo et al., 2014; Seo et al., 2014) inhibition methods for the evaluation of in vitro drug interaction potential have been reported. To date, however, a simultaneous evaluation method for both P450 and UGT enzyme activities has not been developed. The aim of this study was to develop and validate a cocktail assay to simultaneously evaluate the activity of hepatic P450 and UGT isoforms in HLMs using LC-MS/MS.
P450 and UGT are representative phase I and II enzymes responsible for the biotransformation of a wide variety of drugs (Evans and Relling, 1999) . Among the numerous P450 and UGT enzymes identified to date, five P450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A) and four UGT (UGT1A1, UGT1A4, UGT1A9, and UGT2B7) enzymes have been shown to play an important role in the metabolism of marketed drugs. P450 enzymes biotransform about 75% of all drugs, and the above mentioned five P450 human isoforms biotransform about 95% of marketed drugs (Baj-Rossi et al., 2011) . In the case of UGT enzymes, UGT2B7 was suggested to be responsible for the hepatic glucuronidation of 40% of drugs, while UGT1A1, 1A4, and 1A9 contribute to additional 47% (Williams et al., 2004; Burchell et al., 2005) . Based on these data, we attempted to develop a method for the simultaneous evaluation of the activities of five P450 (P450s 1A2, 2C9, 2C19, 2D6, and 3A) and four UGT (UGTs 1A1, 1A4, 1A9, and 2B7) enzyme, which are primarily responsible for drug metabolism.
The optimum incubation conditions for the assessment of enzyme activities are different between the P450 and UGT enzymes. The microsomal incubation of P450 enzymes was conducted in phosphate buffer, whereas UGT enzymes were incubated in Tris-HCl buffer.
UGT enzyme activity was assessed in the presence of alamethicin, a membrane permeabilizing agent (Fisher et al., 2000) and saccharolactone, a β-glucuronidase inhibitor (Oleson and Court, 2008 ) using a longer incubation time (1 hr). In addition, UDPGA also has inhibitory potential against CYP2C9 and CYP2C19 activity to some degree (Yan and Caldwell, 2003) . Therefore, we used two separate microsomal incubations with P450 and UGT probe substrates. The substrates were divided into two cocktail groups (cocktail A for five P450 probe substrates and cocktail B for four UGT probe substrates). These two cocktail mixtures were pooled after incubation and analyzed together using LC-MS/MS to reduce the assay time.
The selection of specific probe substrates for each P450 and UGT enzyme is important because multiple enzymes are involved in the metabolism of a single drug. Therefore, in this study we chose specific probe substrates for the nine major P450 and UGT enzymes in the human liver based on previous reports (Table 1) . Phenacetin, dextromethorphan, and midazolam are the most frequently employed probe substrate for in vitro activity assessment of CYP1A2, CYP2D6, and CYP3A enzymes, respectively, using the cocktail approach, and are also the preferred probes for regulatory authorities Otten et Diclofenac (Dierks et al., 2001; Smith et al., 2007; Pillai et al., 2013) and tolbutamide (Bu et al., 2001; Testino and Patonay, 2003; Kim et al., 2005; He et al., 2007; Tolonen et al., 2007; Otten et al., 2011; Joo and Liu, 2013) are generally used as CYP2C9 probe substrates. In this study, diclofenac was selected as the CYP2C9 probe substrate, because it showed higher detection intensity than tolbutamide in the proposed LC-MS/MS method. Based our preliminary findings, phenacetin, diclofenac, S-mephenytoin, dextromethorphan, and midazolam were selected as the CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A probe substrates, respectively (cocktail A set). For the cocktail B set (UGT enzymes) SN-38, trifluoperazine, mycophenolic acid, and naloxone were selected as probe substrates for UGT1A1, UGT1A4, UGT1A9, and UGT2B7, respectively, based on previously reported data (Uchaipichat et al., 2004; Di Marco et al., 2005; Picard et al., 2005) and our recently published data (Joo et al., 2014) .
Following the selection of the P450 and UGT probe substrates for the cocktail incubation study, the potential metabolic interactions among the five P450 metabolites and four UGT metabolites of the selected probe substrates were evaluated. The simultaneous incubation of five or four substrates may lead to interactions. As shown in metabolizing enzyme phenotyping. The well-known P450 and UGT inhibitors include α-naphthoflavone for CYP1A2 (von Moltke et al., 1996) , sulfaphenazole for CYP2C9 (Khojasteh et al., 2011) , S-benzylnirvanol for CYP2C19 (Suzuki et al., 2002) , quinidine for CYP2D6 (Khojasteh et al., 2011) , ketoconazole for CYP3A (Khojasteh et al., 2011) , hecogenin for UGT1A4 (Uchaipichat et al., 2006) , and niflumic acid for UGT1A9 (Miners et al., 2011) . Atazanavir (Zhang et al., 2005) and mefenamic acid (Mano et al., 2007) are known inhibitors of UGT1A1 and UGT2B7, respectively. Our results demonstrated that α-naphthoflavone, sulfaphenazole, S-benzylnirvanol, quinidine, hecogenin, and niflumic acid strongly and selectively inhibited CYP1A2, CYP2C9, CYP2C19, CYP2D6, UGT1A4, and UGT1A9, respectively (Table 3 and Fig. 5 ). Liu et al. (2011) also reported that selective P450
inhibitors such as α-naphthoflavone, sulfaphenazole, and quinidine have negligible inhibitory potential against UGT isoforms. Ketoconazole also selectively inhibits CYP3A with an IC 50 value of 0.03 μM, which is at least 100-fold more selective compared to its effects against all other P450s and UGTs tested (Fig. 5E ) (Ren et al., 2013) . The inhibitory potential of ketoconazole on UGT1A1-mediated SN-38 glucuronidation (IC 50 = 4.8 μM) concurred with previous findings in which ketoconazole had inhibitory potential on UGT1A1-catalyzed β-estradiol glucuronidation (IC 50 = 4.1 μM) . Hecogenin and niflumic acid are UGT1A4 and UGT1A9 selective inhibitor, respectively, and they have negligible inhibitory
effect on the P450 isoforms tested (IC 50 > 20 μM, Table 3 ). Atazanavir strongly inhibited UGT1A1 activity with an IC 50 value of 0.4 μM, however it also inhibited CYP3A activity (IC 50 = 1.8 μM, Fig. 5F ). Mefenamic acid inhibited UGT2B7 activity (IC 50 = 5.0 μM), but also weakly inhibited CYP1A2 and CYP2C9 activity with IC 50 values of 8.3 and 12 μM, respectively (Fig. 5I) .
We also evaluated the IC 50 values of the characterized inhibitors for each P450 and UGT D M D # 6 3 0 1 6 1 7 enzymes using both the individual and the cocktail substrates (Fig. 4) . The IC 50 value of each cocktail set using this approach was comparable to those of the individual substrates and were in agreement with those previously reported ( Table 2 ). This confirms that the IC 50 values of P450 and UGT inhibitors can be accurately determined using the cocktail assay instead of individual substrate incubations, which would save considerable time in the screening process for new chemical entities. One exception observed was in the inhibition of CYP2C19 by Sbenzylnirvanol, which showed a slight difference compared with previously published values.
The published IC 50 value of 0.41
mephenytoin hydroxylaiton activity (Walsky and Obach, 2003) , was lower than our present Table 2 ). Such a difference is not unusual and could be due to the use of different microsomal incubation conditions (Dierks et al., 2001) . Nonetheless, our results demonstrate that the IC 50 values of inhibitors against the nine enzymes can be determined accurately by cocktail incubation and cassette analysis thereby reducing the time required.
In conclusion, we developed an LC-MS/MS method for the simultaneous determination of five P450 and four UGT enzyme activities. Nine substrates were divided into two cocktail sets for incubation and pooled for LC-MS/MS analysis in a single run. This process allowed us to simultaneously evaluate the activity of five P450 and four UGT enzyme activities, using well-known P450-and UGT-isoform specific inhibitors. In addition, this cocktail method involving multiple substrates, provided inhibition profiles similar to those obtained from single substrate incubations. Therefore, these results suggest that this newly developed assay can be a useful tool for robust and rapid screening, which accelerates the prediction of the 
